Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Rami, Komrokji"'
Autor:
Fabio Efficace, Rena Buckstein, Gregory A. Abel, Johannes M. Giesinger, Pierre Fenaux, Jan Philipp Bewersdorf, Andrew M. Brunner, Rafael Bejar, Uma Borate, Amy E. DeZern, Peter Greenberg, Gail J. Roboz, Michael R. Savona, Francesco Sparano, Jacqueline Boultwood, Rami Komrokji, David A. Sallman, Zhuoer Xie, Guillermo Sanz, Hetty E. Carraway, Justin Taylor, Stephen D. Nimer, Matteo Giovanni Della Porta, Valeria Santini, Maximilian Stahl, Uwe Platzbecker, Mikkael A. Sekeres, Amer M. Zeidan
Publikováno v:
HemaSphere, Vol 8, Iss 5, Pp n/a-n/a (2024)
Abstract Notable treatment advances have been made in recent years for patients with myelodysplastic syndromes/neoplasms (MDS), and several new drugs are under development. For example, the emerging availability of oral MDS therapies holds the promis
Externí odkaz:
https://doaj.org/article/cf17fd5c0de047b1a6c103df622ef528
Autor:
Barbara Mora, Margherita Maffioli, Elisa Rumi, Paola Guglielmelli, Marianna Caramella, Andrew Kuykendall, Francesca Palandri, Alessandra Iurlo, Valerio De Stefano, Jean‐Jacques Kiladjian, Elena M. Elli, Nicola Polverelli, Jason Gotlib, Francesco Albano, Richard T. Silver, Giulia Benevolo, David M. Ross, Timothy Devos, Oscar Borsani, Tiziano Barbui, Matteo G. Della Porta, Lorenza Bertù, Rami Komrokji, Alessandro M. Vannucchi, Francesco Passamonti
Publikováno v:
eJHaem, Vol 4, Iss 3, Pp 679-689 (2023)
Abstract Myelofibrosis (MF) is a clonal malignancy frequently characterized by anemia and in 10%–20% of cases it can evolve into blast phase (BP). Anemia in MF is associated with reduced survival and ‐in primary MF‐ also with an increased proba
Externí odkaz:
https://doaj.org/article/26a6053aeda245cdaafd073cb35b9304
Autor:
Akriti G. Jain, Somedeb Ball, Luis Aguirre, Najla Al Ali, David Kaldas, Sara Tinsley-Vance, Andrew Kuykendall, Onyee Chan, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami Komrokji
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
The patterns of low risk myelodysplastic syndrome (MDS) progression, and the clinical and molecular features of those patterns are not well described. We divided our low risk (LR) MDS patients (n=1914) into 4 cohorts: 1) Patients who remained LR-MDS
Externí odkaz:
https://doaj.org/article/8c6b1ac7b01a432c91e1cb0cd4fc8575
Autor:
Andrew M. Brunner, Alexander Gavralidis, Najla Al Ali, Anthony Hunter, Rami Komrokji, Amer Zeidan, David A. Sallman
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 11, Pp 1-6 (2022)
Following treatment with DNMTI therapy, patients with MDS have differences in survival according to the quality of their treatment response. In this analysis, patients who achieve CRh had similar OS compared to those meeting standard “CR” criteri
Externí odkaz:
https://doaj.org/article/383dd7c757d94ef89eb58a9a3c7829dc
Autor:
Abhishek A. Mangaonkar, Terra L. Lasho, Rhett P. Ketterling, Kaaren K. Reichard, Naseema Gangat, Aref Al-Kali, Kebede H. Begna, Animesh Pardanani, Najla H. Al Ali, Chetasi Talati, David Sallman, Eric Padron, Mrinal M. Patnaik, Ayalew Tefferi, Rami Komrokji
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 2, Pp 1-6 (2022)
Abstract The current World Health Organization (WHO) classification of myeloid malignancies includes myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) as a distinct entity. Previous literature on pr
Externí odkaz:
https://doaj.org/article/8153cb3623324da3b83edb09eee43e17
Autor:
Rami Komrokji, Najla al Ali, Onyee Chan, Kendra Sweet, Andrew Kuykendall, Jeffrey Lancet, Eric Padron, David A. Sallman
Publikováno v:
Haematologica, Vol 108, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/f064c888f14940f8adceece9c5c76cae
Autor:
Nathan Radakovich, David A. Sallman, Rena Buckstein, Andrew Brunner, Amy Dezern, Sudipto Mukerjee, Rami Komrokji, Najla Al-Ali, Jacob Shreve, Yazan Rouphail, Anne Parmentier, Alexandre Mamedov, Mohammed Siddiqui, Yihong Guan, Teodora Kuzmanovic, Metis Hasipek, Babal Jha, Jaroslaw P. Maciejewski, Mikkael A. Sekeres, Aziz Nazha
Publikováno v:
iScience, Vol 25, Iss 10, Pp 104931- (2022)
Summary: Hypomethylating agents (HMA) prolong survival and improve cytopenias in individuals with higher-risk myelodysplastic syndrome (MDS). Only 30-40% of patients, however, respond to HMAs, and responses may not occur for more than 6 months after
Externí odkaz:
https://doaj.org/article/2af0555cd0c8408793d44b3da7b87d0f
Autor:
Abhishek A. Mangaonkar, Terra L. Lasho, Christy Finke, Rhett P. Ketterling, Kaaren K. Reichard, Kristen McCullough, Naseema Gangat, Aref Al-Kali, Kebede H. Begna, William H. Hogan, Mark R. Litzow, Hassan Alkhateeb, Mithun Shah, Animesh Pardanani, Ayalew Tefferi, Najla H. Al Ali, Chetasi Talati, David Sallman, Eric Padron, Rami Komrokji, Mrinal M. Patnaik
Publikováno v:
Haematologica, Vol 107, Iss 5 (2022)
Externí odkaz:
https://doaj.org/article/058bd801e0344842925958441b67cbc2
Autor:
Barbara Mora, Elisa Rumi, Paola Guglielmelli, Daniela Barraco, Margherita Maffioli, Alessandro Rambaldi, Marianna Caramella, Rami Komrokji, Jason Gotlib, Jean Jacques Kiladjian, Francisco Cervantes, Timothy Devos, Francesca Palandri, Valerio DeStefano, Marco Ruggeri, Richard T. Silver, Giulia Benevolo, Francesco Albano, Chiara Cavalloni, Daniela Pietra, Tiziano Barbui, Giada Rotunno, Mario Cazzola, Alessandro Maria Vannucchi, Toni Giorgino, Francesco Passamonti
Publikováno v:
Cancer Medicine, Vol 8, Iss 9, Pp 4089-4092 (2019)
Abstract Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the i
Externí odkaz:
https://doaj.org/article/b3c1fbb84b8d4cc1b95425cd156db14e
Autor:
Abu-Sayeef Mirza, Seongseok Yun, Najla Al Ali, Hannah Shin, Joseph Luke O’Neil, Maher Elharake, Daniel Schwartz, Katherine Robinson, Ethan Nowell, Grace Engle, Ibraahim Badat, Thomas Brimer, Amra Kuc, Ashton Sequeira, Sabbir Mirza, Dhiraj Sikaria, Jesus Diaz Vera, Noah Hackney, Sammy Abusrur, Jose Jesurajan, Jameson Kuang, Shreyans Patel, Sabrina Khalil, Sonya Bhaskar, Alexander Beard, Toaa Abuelenen, Kevin Ratnasamy, Nathan Visweshwar, Rami Komrokji, Michael Jaglal
Publikováno v:
Thrombosis Journal, Vol 17, Iss 1, Pp 1-6 (2019)
Abstract Background Although patients with acute myeloid leukemia (AML) were shown to have an increased risk of thrombosis, no thrombosis risk assessment scoring system has been developed for AML patients. The Khorana Risk Score (KRS), which has been
Externí odkaz:
https://doaj.org/article/946616b33ff840a6913dcc6fedad322e